Ignite Creation Date:
2024-05-05 @ 11:00 PM
Last Modification Date:
2024-10-26 @ 10:27 AM
Study NCT ID:
NCT01231594
Status:
COMPLETED
Last Update Posted:
2019-03-22
First Post:
2010-10-21
Brief Title:
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This rollover study is designed to provide continued access to GSK2118436 for eligible subjects with BRAF mutation-positive tumors who have previously participated in a GlaxoSmithKline GSK-sponsored GSK2118436 study parent study who have no evidence of progressive disease and who have tolerated GSK2118436 in the parent study without significant toxicities Subjects will be enrolled into the appropriate cohort based upon the treatment received in their parent study Safety assessments physical examinations vital signs 12-lead electrocardiograms echocardiograms clinical laboratory assessments and monitoring of adverse events will be made throughout the study Clinical activity will be assessed using local standard of care imaging practices and the appropriate response criteria as determined by the investigator
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None